This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Xospata (gilteritinib)
General Description:
Xospata (gilteritinib) is an oral targeted therapy used for the treatment of adults with FLT3 mutation–positive (FLT3m+) acute myeloid leukemia (AML) whose disease has relapsed or is refractory after previous treatment. It works by inhibiting FLT3, a receptor tyrosine kinase involved in leukemia cell proliferation and survival, thereby helping to control disease progression.
Xospata is administered orally, and dosing is determined by a qualified healthcare professional based on patient condition and treatment response.
Getting Xospata (gilteritinib) in India
Xospata has been approved by several leading international regulatory agencies, including the European Medicines Agency (EMA), Health Canada, and the Therapeutic Goods Administration (TGA). While it may not yet be commercially available in India, patients can access it legally through a Named Patient Program (NPP) under physician supervision.
MitoGENE helps Indian patients obtain Xospata safely and compliantly by managing all regulatory documentation, import permits, and logistics to ensure a transparent and secure supply process.
Disease Indication:
• FLT3 Mutation–Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Manufacturer:
Astellas Pharma Inc.
Usage:
Oral Tablets
Medicine Approved By:
• European Medicines Agency (EMA)
• Health Canada
• Therapeutic Goods Administration (TGA)
Available Dosage Form & Package:
• 84 tablets of 40 mg
Shipping:
Room Temperature Shipping
Xospata is shipped under controlled room temperature conditions (15–25°C) to maintain its stability and therapeutic effectiveness. Standard shipping practices ensure the medicine remains uncompromised throughout transit.
How to Access Xospata (gilteritinib) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?
If Xospata (gilteritinib) is not yet approved or commercially available in India, MitoGENE can assist you in accessing it legally through the Named Patient Program (NPP). Here’s how the process works:
